CORAL SPRINGS, Florida, April 11, 2013 /PRNewswire/ --
FinancialNewsMedia.com issues market news report for today's Active HealthCare Companies: Embark Holdings, Inc., Vitamin Shoppe, Inc. (NYSE: VSI), MusclePharm Corporation, Repros Therapeutics Inc.(NASDAQ: RPRX), Unilife Corporation (NASDAQ: UNIS) and Pfizer Inc. (NYSE: PFE)
Embark Holdings, Inc. a leader in providing research, evaluation and acquisition services to businesses throughout the world, announced acquiring 100% of Muscle Warfare, Inc. (http://musclewarfare.com) a company that develops, manufactures, and markets sports nutrition products of the highest quality for athletes around the world in all sports, including both professional and amateur enthusiasts. The acquisition consisted of preferred shares in Embark Holdings, Inc. Muscle Warfare products are certified banned substance free by the World Anti-Doping Agency ("WADA") standards and are tested in one of the most elite testing labs in the world called HFL Sport Science, the world's largest and most experienced sports test laboratory. The HFL laboratory is ISO Certified and accredited for forensic testing and meets or exceeds world anti-doping agency standards and requirements. The company's processes ensure that the product offerings distributed are free of inadvertent contaminants and are not deliberately spiked with contaminant compounds by many raw material manufacturers. Muscle Warfare is now distributing product in approximately 550+ Vitamin Shoppe (NYSE: VSI) stores Nationwide. Also, they have a very strong partnership with Europa, the largest independent sports nutrition distributor in the U.S.; along with many Large scale International Clients, which it believes will help continue our growth trajectory. Read the full press release at http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=257
Vitamin Shoppe, Inc. (NYSE: VSI), a leading multi-channel specialty retailer of nutritional products, announced this week the company's Senior Vice President, General Counsel & Corporate Secretary, Jean Frydman, has been selected as a finalist in the public company with revenues over $1 billion category in the 2013 NJBIZ General Counsel of the Year Awards program. The annual NJBIZ award program recognizes New Jersey's leading General Counsels, Chief Legal Officers and corporate compliance officers and their key achievements for the companies they work for. Ms. Frydman joined the Vitamin Shoppe in May 2012, and during her tenure has guided the company through the acquisition of Super Supplements, the largest acquisition in the company's history. She has also guided the company through the lease process for new corporate office space and a new distribution center planned to open this summer during a period of increasing growth for the company.
MusclePharm Corporation, a nutritional supplement company focused on active lifestyles, announced today it continues to see strengthening demand for its line of branded sports nutritional products in international markets. During the year ended December 31, 2012, gross sales of MusclePharm products in international markets grew to approximately $27 million, an increase of over 550% as compared to gross sales of $4 million in 2011. In 2012, international sales accounted for approximately 35% of overall sales, up from 19% in 2011.
Repros Therapeutics Inc. (NASDAQ: RPRX) announced this week two patents representing potentially large commercial indications for its drug Androxal have been issued. The two patents deal with the metabolic consequences of low testosterone and the positive outcomes associated with restoration of testicular function exhibited by Androxal. The 8,377,991 patent specifically covers treatment of Type 2 diabetes, an area of high unmet medical need. The 991 issuance and patent life should have a positive impact on Androxal's long-term commercial potential.
Unilife Corporation (NASDAQ: UNIS) announced yesterday the signing of a Customization and Commercial Supply Agreement with a U.S. pharmaceutical company for the EZMix(TM) dual-chamber syringe. Unilife will supply the Customer with a customized device from its EZMix platform of dual-chamber delivery systems for use with a lyophilized drug that requires mixing at the time of injection. The Drug, which is a proprietary version of an approved therapy, is entering late-stage clinical development with the Customer planning an accelerated pathway to U.S. regulatory approval.
Pfizer Inc. (NYSE: PFE) says U.S. regulators have classified its experimental pill for advanced, often-deadly breast cancer as a breakthrough therapy. That's done to speed up development and review of treatments seen as big advances. Palbociclib is in late-stage testing as an initial treatment for the biggest subgroup of postmenopausal women with advanced breast cancer - those in whom tumor growth is fueled by the hormone estrogen but not by a growth-promoting protein called HER2.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC